An International Study on Pediatric Patients With Rare Tumors.

NCT07072143 | Recruiting DMC

• 1 other identifier: The PARTNER study (AOP3417)
• Study Type: observational
• Target: 6,250
• Locations: 1 country
• Sites: 1

Brief Summary

The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.

Conditions

Paraganglioma/ Phaeochromocytoma; Melanoma and Other Malignant Neoplasms of Skin; Gastrointestinal Stromal Tumor (GIST); Adrenocortical Tumor; Pancreatic Tumors; Esthesioneuroblastoma, Olfactory; Mesothelioma; Nasopharyngeal Carcinoma (NPC); NUT Carcinoma; Pleuropulmonary Blastoma; Salivary Gland Tumors; Thymic Tumors; Thyroid Carcinoma; Appendiceal Cancers

Keywords

children; rare tumors; very rare tumors; adolescents; PARTNER Study

Outcome Measures

Primary Outcomes (3)

• Epidemiology

  Evaluate the number of patients (aged 0-18 years) with different Very Rare Tumors in the different countries: observed cases will be compared with expected cases.

  through study completion, an average of 1 year

• Use of International Recommendations

  The study aims to measure the number of patients treated for different neoplasms in different countries, and the proportion of those treated in accordance with the International Recommendations.

  through study completion, an average of 1 year

• Survival of children and adolescents (0-18 years) affected by Very Rare Tumors

  The study will correlate the clinical characteristics of the tumor (size, site, extension) with the treatment, the risk of recurrence and survival.

  through study completion, an average of 1 year

Eligibility Criteria

• Age: 0 Years - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Children and adolescents (0-18 years) with a primary or relapsed Very Rare Tumor (VRT)

You may qualify if:

• Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and/or treated in a participating country/center.
• Written informed consent from the patient and/or the parent/legal guardian

You may not qualify if:

• Absence of Written informed consent from the patient and/or the parent/legal guardian

Sponsors & Collaborators

• Azienda Ospedaliera di Padova: lead
• St. Anna Children's Hospital, Vienna: collaborator
• Children's Hospital Zagreb: collaborator
• Centre Hospitalier Universitaire de La Réunion, FRANCE: collaborator
• Klinikum Dortmund: collaborator
• University Children's Hospital Tuebingen: collaborator
• Hellenic Oncology Research Group: collaborator
• Fondazione IRCCS Istituto Nazionale dei Tumori, Milano: collaborator
• Kaplan Medical Center, Rehovot, Israel: collaborator
• Vilnius University hospital Santaros klinikos, Vilnius, Lithuania: collaborator
• University of Skopje: collaborator
• Gdansk Medical University (Poland): collaborator
• Centro Hospitalar do Porto: collaborator
• Bucharest Emergency Hospital: collaborator
• Institute for Oncology and Radiology Serbia, Belgrade: collaborator
• University Hospital Bratislava: collaborator
• University Medical Centre Ljubljana: collaborator
• University of Bilbao: collaborator
• Göteborg University: collaborator
• University Hospital, Paris: collaborator

Study Sites (1)

Pediatric Oncology Unit, University Hospital Padova [AOUP Azienda Ospedale Università Padova]

Padua, Italy, 35127, Italy

RECRUITING

Related Publications (1)

• Orbach D, Ferrari A, Schneider DT, Reguerre Y, Godzinski J, Bien E, Stachowicz-Stencel T, Surun A, Almaraz RL, Dragomir M, Jani D, Ami TB, Roganovic J, Brecht IB, Ladenstein R, Bisogno G. The European Paediatric Rare Tumours Network - European Registry (PARTNER) project for very rare tumors in children. Pediatr Blood Cancer. 2021 Jun;68 Suppl 4:e29072. doi: 10.1002/pbc.29072. Epub 2021 Apr 29.

  PMID: 33913610 BACKGROUND

Related Links

• The page describes the PARTNER project inside the website of SIOP Europe (the European Society for Paediatric Oncology)

MeSH Terms

Conditions

Melanoma; Gastrointestinal Stromal Tumors; Adrenal Cortex Neoplasms; Pancreatic Neoplasms; Esthesioneuroblastoma, Olfactory; Mesothelioma; Nasopharyngeal Carcinoma; Pleuropulmonary blastoma; Thymus Neoplasms; Thyroid Neoplasms

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases; Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Adrenal Gland Neoplasms; Endocrine Gland Neoplasms; Adrenal Cortex Diseases; Adrenal Gland Diseases; Endocrine System Diseases; Pancreatic Diseases; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Neuroectodermal Tumors, Primitive; Neoplasms, Neuroepithelial; Neoplasms, Glandular and Epithelial; Olfactory Nerve Diseases; Cranial Nerve Diseases; Nervous System Diseases; Adenoma; Neoplasms, Mesothelial; Carcinoma; Nasopharyngeal Neoplasms; Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Nasopharyngeal Diseases; Pharyngeal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases; Thoracic Neoplasms; Lymphatic Diseases; Hemic and Lymphatic Diseases; Thyroid Diseases

Study Officials

• Gianni Bisogno, MD

  Azienda Ospedale Università Padova - Italy

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Gianni Bisogno, MD

CONTACT

0039 0498211481; gianni.bisogno@unipd.it

Martina Bonel, CRC

CONTACT

0039 04908211481; martina.bonel@unipd.it

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Paediatrics

Study Record Dates

• First Submitted: April 15, 2025
• First Posted: July 18, 2025
• Study Start: January 25, 2025
• Primary Completion (Estimated): January 6, 2049
• Study Completion (Estimated): June 6, 2049
• Last Updated: July 18, 2025

Record last verified: 2025-07

Locations

IT (1)